July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Novel gene therapy for proliferative vitreoretinopathy.
Author Affiliations & Notes
  • Ting-Chia Wong
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Sijia Cao
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Amelia Tjoa
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Ho-Young Jung
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Ljubomir Kojic
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • William Jia
    Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
  • Max S. Cynader
    Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia, Canada
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Jing Z Cui
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Joanne A Matsubara
    Department of Ophthalmology & Visual Sciences, University of British Columbia, Vancouver, British Columbia, Canada
  • Footnotes
    Commercial Relationships   Ting-Chia Wong, None; Sijia Cao, None; Amelia Tjoa, None; Ho-Young Jung, None; Ljubomir Kojic, None; William Jia, None; Max Cynader, None; Jing Cui, None; Joanne Matsubara, None
  • Footnotes
    Support  US Department of Defense/Defense Medical Research and Development Program (MR130584), Canadian Institutes of Health Research
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ting-Chia Wong, Sijia Cao, Amelia Tjoa, Ho-Young Jung, Ljubomir Kojic, William Jia, Max S. Cynader, Jing Z Cui, Joanne A Matsubara; Novel gene therapy for proliferative vitreoretinopathy.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Ocular trauma and retinal surgery often result in proliferative vitreoretinopathy (PVR), a form of vision-compromising intraocular fibrosis. A key process in PVR is local inflammation. We tested the hypothesis that a modified, injury-triggered interleukin-1 receptor antagonist (IL-1ra), delivered via intraocular gene therapy, can be used to prevent PVR-related tissue damage in an experimental rabbit model of traumatic eye injury.

Methods : We engineered a chimeric transmembrane protein with an extracellular IL-1ra domain that is tethered to the cell surface by a protein sequence cleavable by metalloproteinases activated by local inflammation. Upon traumatic insult, anti-inflammatory IL-1ra was released into the extracellular matrix. These proteins were expressed under either the ubiquitin or cytomegalovirus (CMV) promoters and delivered via adeno-associated viruses. A non-cleavable protein was used as a control.

The vectors were delivered in vivo as a subretinal injection (~5 x 1010 vg/eye) in rabbits. A no-treatment control group received phosphate-buffered saline injection only. PVR was then induced through a single intravitreal injection of autologous blood. Animals were sacrificed at 4 days and at 12 weeks post-PVR induction. Immunohistochemistry for ionized calcium-binding adaptor molecule 1 (Iba1) was performed on paraffin-embedded tissue. Iba1 was used to stain for microglia, which are activated and recruited during local inflammation.

We counted the mean number of retinal microglia per high-power field in each eye using confocal microscopy. Unpaired Student’s t-test was used to compare treatment groups (N=2).

Results : At 4 days post-PVR induction, the mean number of retinal microglia in the rabbits that did not receive gene therapy was 2.1 (SEM=0.3). A reduction was observed in eyes receiving CMV-IL-1ra (0.8±0.2, p=0.0598) and ubiquitin-IL-1ra (1.2±0.0, p=0.0767). However, no anti-inflammatory effect was seen with the non-cleavable protein (2.1±0.1, p=0.8698) that could not release IL-1ra. Similarly, at 12 weeks post-PVR induction, fundus photographs of eyes treated with non-cleavable protein revealed large intravitreal membranes, which represent PVR-related changes, while those with the two cleavable molecules had subjectively smaller membranes.

Conclusions : Using injury-responsive IL-1ra gene therapy, we were able to reduce post-trauma inflammation acutely and also mitigate the long-term structural changes associated with PVR.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×